Compare Stocks: CNTB, ANL, ARTV, and CABA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANL Adlai Nortye	$13.82 -3.5%	$12.16	$0.88 ▼ $17.25	$552.80M	1.06	158,975 shs	165,028 shs
ARTV Artiva Biotherapeutics	$11.09 -7.1%	$10.38	$2.22 ▼ $14.53	$542.19M	2.16	322,027 shs	222,786 shs
CABA Cabaletta Bio	$3.12 -7.7%	$2.92	$1.40 ▼ $4.23	$528.98M	3.3	4.28 million shs	3.23 million shs
CNTB Connect Biopharma	$2.23 -2.2%	$2.27	$1.23 ▼ $3.82	$140.43M	-0.23	442,489 shs	339,135 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANL Adlai Nortye	0.00%	+0.88%	+6.31%	+15.75%	+717.27%
ARTV Artiva Biotherapeutics	0.00%	+1.46%	+6.33%	+39.85%	+239.14%
CABA Cabaletta Bio	0.00%	-0.32%	+14.71%	-17.46%	+108.00%
CNTB Connect Biopharma	0.00%	-5.51%	+6.70%	-10.44%	+25.28%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANL Adlai Nortye	$13.82 -3.5%	$12.16	$0.88 ▼ $17.25	$552.80M	1.06	158,975 shs	165,028 shs
ARTV Artiva Biotherapeutics	$11.09 -7.1%	$10.38	$2.22 ▼ $14.53	$542.19M	2.16	322,027 shs	222,786 shs
CABA Cabaletta Bio	$3.12 -7.7%	$2.92	$1.40 ▼ $4.23	$528.98M	3.3	4.28 million shs	3.23 million shs
CNTB Connect Biopharma	$2.23 -2.2%	$2.27	$1.23 ▼ $3.82	$140.43M	-0.23	442,489 shs	339,135 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANL Adlai Nortye	0.00%	+0.88%	+6.31%	+15.75%	+717.27%
ARTV Artiva Biotherapeutics	0.00%	+1.46%	+6.33%	+39.85%	+239.14%
CABA Cabaletta Bio	0.00%	-0.32%	+14.71%	-17.46%	+108.00%
CNTB Connect Biopharma	0.00%	-5.51%	+6.70%	-10.44%	+25.28%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANL Adlai Nortye	2.67	Moderate Buy	$24.25	75.47% Upside
ARTV Artiva Biotherapeutics	2.83	Moderate Buy	$39.00	251.67% Upside
CABA Cabaletta Bio	2.75	Moderate Buy	$15.33	391.45% Upside
CNTB Connect Biopharma	2.75	Moderate Buy	$7.43	233.12% Upside

Current Analyst Ratings Breakdown

Latest CNTB, ANL, ARTV, and CABA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	CABA Cabaletta Bio	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/14/2026	CNTB Connect Biopharma	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$7.00
8/14/2026	CABA Cabaletta Bio	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$4.00 ➝ $3.00
7/21/2026	ARTV Artiva Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	CABA Cabaletta Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	ANL Adlai Nortye	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/9/2026	CNTB Connect Biopharma	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
6/30/2026	CNTB Connect Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
6/26/2026	CNTB Connect Biopharma	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral ➝ Overweight	$7.00
6/26/2026	CNTB Connect Biopharma	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral ➝ Overweight	$7.00
6/25/2026	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$7.00

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANL Adlai Nortye	$5M	110.56	N/A	N/A	$5.37 per share	2.57
ARTV Artiva Biotherapeutics	$250K	2,168.76	N/A	N/A	$7.11 per share	1.56
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$1.24 per share	N/A
CNTB Connect Biopharma	$60K	2,340.39	N/A	N/A	$0.43 per share	5.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANL Adlai Nortye	-$35.53M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ARTV Artiva Biotherapeutics	-$83.86M	-$3.30	N/A	N/A	N/A	N/A	-53.86%	-48.16%	11/11/2026 (Estimated)
CABA Cabaletta Bio	-$167.86M	-$1.57	N/A	N/A	N/A	N/A	-128.27%	-95.47%	11/9/2026 (Estimated)
CNTB Connect Biopharma	-$55.48M	-$1.19	N/A	N/A	N/A	N/A	-165.41%	-121.58%	11/11/2026 (Estimated)

Latest CNTB, ANL, ARTV, and CABA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CABA Cabaletta Bio	-$0.3729	-$0.34	+$0.0329	-$0.34	$1.67 million	N/A
8/12/2026	Q2 2026	CNTB Connect Biopharma	-$0.3149	-$0.27	+$0.0449	-$0.27	$0.74 million	$2.75 million
8/6/2026	Q2 2026	ARTV Artiva Biotherapeutics	-$0.6251	-$0.63	-$0.0049	-$0.63	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANL Adlai Nortye	N/A	N/A	N/A	N/A	N/A
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANL Adlai Nortye	0.04	9.55	0.65
ARTV Artiva Biotherapeutics	N/A	24.16	24.16
CABA Cabaletta Bio	N/A	5.79	5.79
CNTB Connect Biopharma	0.01	2.37	2.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANL Adlai Nortye	35.21%
ARTV Artiva Biotherapeutics	N/A
CABA Cabaletta Bio	N/A
CNTB Connect Biopharma	58.72%

Insider Ownership

Company	Insider Ownership
ANL Adlai Nortye	N/A
ARTV Artiva Biotherapeutics	1.80%
CABA Cabaletta Bio	6.44%
CNTB Connect Biopharma	22.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANL Adlai Nortye	127	40.00 million	N/A	Not Optionable
ARTV Artiva Biotherapeutics	81	48.89 million	48.01 million	N/A
CABA Cabaletta Bio	50	169.54 million	158.63 million	Optionable
CNTB Connect Biopharma	110	62.97 million	48.74 million	Optionable

CNTB, ANL, ARTV, and CABA Headlines

Recent News About These Companies

Analysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (CNTB) and Stryker (SYK)

August 28 at 5:43 PM | theglobeandmail.com

HC Wainwright Issues Pessimistic Forecast for CNTB Earnings

August 17, 2026 | marketbeat.com

Connect Biopharma (NASDAQ:CNTB) Upgraded by Wall Street Zen to Hold Rating

August 15, 2026 | marketbeat.com

Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update

August 12, 2026 | finance.yahoo.com

Connect Biopharma (NASDAQ:CNTB) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS

August 12, 2026 | marketbeat.com

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Average Rating of "Moderate Buy" by Analysts

August 8, 2026 | marketbeat.com

Connect Biopharma (CNTB) Projected to Release Earnings on Wednesday

August 5, 2026 | marketbeat.com

Connect Biopharma: Attempting To Differentiate Rademikibart From Dupixent

July 23, 2026 | seekingalpha.com

Connect Biopharma Holdings (CNTB) Receives a New Rating from Oppenheimer

July 10, 2026 | theglobeandmail.com

Analysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY), Alkermes (ALKS) and Connect Biopharma Holdings (CNTB)

June 19, 2026 | theglobeandmail.com

Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

June 17, 2026 | globenewswire.com

Connect Biopharma (NASDAQ:CNTB) Director James Huang Purchases 150,000 Shares

June 3, 2026 | insidertrades.com

Canaccord Genuity initiates coverage of Connect Biopharma Holdings (CNTB) with buy recommendation

May 27, 2026 | msn.com

Cantor Fitzgerald initiates coverage of Connect Biopharma Holdings (CNTB) with overweight recommendation

May 23, 2026 | msn.com

Connect Biopharma touts Rademikibart's edge as SEABREEZE data looms in 2026

May 23, 2026 | msn.com

Connect Biopharma Growth Plans Raise Financial Discipline Focus

May 21, 2026 | kalkinemedia.comK

Companies Like Connect Biopharma Holdings (NASDAQ:CNTB) Could Be Quite Risky

May 15, 2026 | finance.yahoo.com

Connect Biopharma Holdings Ltd.

May 14, 2026 | cnn.com

Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

May 12, 2026 | globenewswire.com

Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026 | globenewswire.com

Connect Biopharma: New Market Opportunity In The Emergency Setting

April 29, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB, ANL, ARTV, and CABA Company Descriptions

Adlai Nortye NASDAQ:ANL

$13.82 -0.50 (-3.49%)

As of 08/28/2026 04:00 PM Eastern

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Artiva Biotherapeutics NASDAQ:ARTV

$11.09 -0.85 (-7.12%)

As of 08/28/2026 04:00 PM Eastern

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Cabaletta Bio NASDAQ:CABA

$3.12 -0.26 (-7.69%)

As of 08/28/2026 04:00 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Connect Biopharma NASDAQ:CNTB

$2.23 -0.05 (-2.19%)

As of 08/28/2026 04:00 PM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CNTB, ANL, ARTV, and CABA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CNTB, ANL, ARTV, and CABA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CNTB, ANL, ARTV, and CABA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB, ANL, ARTV, and CABA Company Descriptions

Adlai Nortye NASDAQ:ANL

Artiva Biotherapeutics NASDAQ:ARTV

Cabaletta Bio NASDAQ:CABA

Connect Biopharma NASDAQ:CNTB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CNTB, ANL, ARTV, and CABA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CNTB, ANL, ARTV, and CABA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CNTB, ANL, ARTV, and CABA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB, ANL, ARTV, and CABA Company Descriptions

Adlai Nortye NASDAQ:ANL

Artiva Biotherapeutics NASDAQ:ARTV

Cabaletta Bio NASDAQ:CABA

Connect Biopharma NASDAQ:CNTB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools